世界の非小細胞肺がん治療薬の市場規模は、2023年に191億ドルと評価され、2024年から2030年にかけて12.7%のCAGRで成長すると予測されます。市場の成長は、肺障害と診断される患者の割合の増加に起因しています。たばこ製品の消費量の増加、大気汚染による大気質の悪化、不健康なライフスタイルも、肺がんの増加の一因となっています。さらに、非小細胞肺がん(NSCLC)に関連する医薬品や治療法の研究開発に対する主要な医療機関による投資の増加が、この市場の成長をもたらしました。
目次
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Non-small cell lung cancer therapeutics market Variables, Trends, & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Non-small Cell Lung Cancer Therapeutics Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
Chapter 4. Non-small Cell Lung Cancer Therapeutics Market: Type Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Non-small Cell Lung Cancer Therapeutics Market: Type Movement Analysis, 2023 & 2030 (USD Million)
4.3. Squamous Cell Carcinoma
4.3.1. Squamous Cell Carcinoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Large Cell Carcinoma
4.5. Large Cell Carcinoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Adenocarcinoma
4.6.1. Adenocarcinoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Others
4.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Non-small Cell Lung Cancer Therapeutics Market: Treatment Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Non-small Cell Lung Cancer Therapeutics Market: Treatment Movement Analysis, 2023 & 2030 (USD Million)
5.3. Chemotherapy
5.3.1. Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Targeted Therapy
5.4.1. Targeted Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Immunotherapy
5.5.1. Immunotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Non-small Cell Lung Cancer Therapeutics Market: Distribution Channel Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Non-small Cell Lung Cancer Therapeutics Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
6.3. Hospital Pharmacy
6.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Drug Store and Retail Pharmacy
6.4.1. Drug Store and Retail Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Online Pharmacy
6.5.1. Online Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Non-small Cell Lung Cancer Therapeutics Market: Regional Estimates & Trend Analysis
7.1. Non-small Cell Lung Cancer Therapeutics Market Share, By Region, 2023 & 2030 (USD Million)
7.2. North America
7.2.1. North America Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. U.S. Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Canada Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.4. Mexico
7.2.4.1. Mexico Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. Europe Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.2. UK
7.3.2.1. UK Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Germany Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.4. France
7.3.4.1. France Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.5. Italy
7.3.5.1. Italy Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.6. Spain
7.3.6.1. Spain Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.7. Denmark
7.3.7.1. Denmark Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.8. Sweden
7.3.8.1. Sweden Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.9. Norway
7.3.9.1. Norway Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.2. Japan
7.4.2.1. Japan Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.3. China
7.4.3.1. China Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.4. India
7.4.4.1. India Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.5. Australia
7.4.5.1. Australia Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.6. South Korea
7.4.6.1. South Korea Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.7. Thailand
7.4.7.1. Thailand Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Brazil Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.3. Argentina
7.5.3.1. Argentina Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Middle East and Africa
7.6.1. Middle East and Africa Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.2. South Africa
7.6.2.1. South Africa Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.3. Saudi Arabia
7.6.3.1. Saudi Arabia Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.4. UAE
7.6.4.1. UAE Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.5. Kuwait
7.6.5.1. Kuwait Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
8.4.1. F. Hoffmann-La Roche Ltd
8.4.1.1. Participant’s Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Recent Developments/ Strategic Initiatives
8.4.2. Mylan N.V.
8.4.2.1. Participant’s Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Recent Developments/ Strategic Initiatives
8.4.3. Teva Pharmaceutical Industries Ltd.
8.4.3.1. Participant’s Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Recent Developments/ Strategic Initiatives
8.4.4. Sanofi
8.4.4.1. Participant’s Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Recent Developments/ Strategic Initiatives
8.4.5. Pfizer Inc.
8.4.5.1. Participant’s Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Recent Developments/ Strategic Initiatives
8.4.6. GSK plc
8.4.6.1. Participant’s Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Recent Developments/ Strategic Initiatives
8.4.7. Novartis AG
8.4.7.1. Participant’s Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Recent Developments/ Strategic Initiatives
8.4.8. Bayer AG
8.4.8.1. Participant’s Overview
8.4.8.2. Financial Performance
8.4.8.3. Product Benchmarking
8.4.8.4. Recent Developments/ Strategic Initiatives
8.4.9. Eli Lilly and Company
8.4.9.1. Participant’s Overview
8.4.9.2. Financial Performance
8.4.9.3. Product Benchmarking
8.4.9.4. Recent Developments/ Strategic Initiatives
8.4.10. Merck & Co., Inc
8.4.10.1. Participant’s Overview
8.4.10.2. Financial Performance
8.4.10.3. Product Benchmarking
8.4.10.4. Recent Developments/ Strategic Initiatives
